Literature DB >> 23355442

Ganglioside GM3 inhibits hepatoma cell motility via down-regulating activity of EGFR and PI3K/AKT signaling pathway.

X Huang1, Y Li, J Zhang, Y Xu, Y Tian, K Ma.   

Abstract

Two related sublines derived from murine ascites hepatoma cell lines Hca-F25, which were selected for their markedly different metastatic potential to lymph nodes, were found to be distinct in their ganglioside patterns. The low metastatic cell line (HcaP) contained a major ganglioside GM3, whereas the high metastatic cell line (HcaF) contained a major ganglioside GM2. Suppression of GM3 by P4 enhanced the mobility and migration of the low metastatic HcaP cells in vitro. Increase in GM3 content in high metastatic HcaF cells by addition of exogenous GM3 inhibited the mobility and migration. These results suggested that the differences in lymphatic metastasis potential between these two cell lines could be attributed to the differences in their ganglioside compositions, and GM3 could suppress the motility and migration of these cells. Further, we investigated the mechanism by which GM3 suppressed the cell mobility and migration. The results showed that suppression of GM3 synthesis by P4 in low metastatic HcaP cells promoted PKB/Akt phosphorylation at Ser473 and Thr308, and phosphorylation of EGFR at the Tyr1173. In contrast, increase in GM3 content in high metastatic HcaF cells by addition of exogenous GM3 into the culture medium suppressed phosphorylation of PKB/Akt and EGFR at the same residues. Taken together, these results suggested that the mechanism of GM3-suppressed cell motility and migration may involve the inhibition of phosphorylation of EGFR and the activity of PI3K/AKT signaling pathway.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23355442     DOI: 10.1002/jcb.24503

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  11 in total

1.  A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation.

Authors:  Luigi Boccuto; Kazuhiro Aoki; Heather Flanagan-Steet; Chin-Fu Chen; Xiang Fan; Frank Bartel; Marharyta Petukh; Ayla Pittman; Robert Saul; Alka Chaubey; Emil Alexov; Michael Tiemeyer; Richard Steet; Charles E Schwartz
Journal:  Hum Mol Genet       Date:  2013-09-10       Impact factor: 6.150

2.  High EGFR_1 Inside-Out Activated Inflammation-Induced Motility through SLC2A1-CCNB2-HMMR-KIF11-NUSAP1-PRC1-UBE2C.

Authors:  Huilei Zhou; Lin Wang; Juxiang Huang; Minghu Jiang; Xiaoyu Zhang; Liyuan Zhang; Yangming Wang; Zhenfu Jiang; Zhongjie Zhang
Journal:  J Cancer       Date:  2015-04-05       Impact factor: 4.207

Review 3.  Role of Cytokine-Induced Glycosylation Changes in Regulating Cell Interactions and Cell Signaling in Inflammatory Diseases and Cancer.

Authors:  Justine H Dewald; Florent Colomb; Marie Bobowski-Gerard; Sophie Groux-Degroote; Philippe Delannoy
Journal:  Cells       Date:  2016-11-29       Impact factor: 6.600

4.  Ganglioside GM1 promotes contact inhibition of growth by regulating the localization of epidermal growth factor receptor from glycosphingolipid-enriched microdomain to caveolae.

Authors:  Dinghao Zhuo; Feng Guan
Journal:  Cell Prolif       Date:  2019-05-24       Impact factor: 6.831

Review 5.  Effects of Gangliosides on Spermatozoa, Oocytes, and Preimplantation Embryos.

Authors:  Bo Hyun Kim; Won Seok Ju; Ji-Su Kim; Sun-Uk Kim; Soon Ju Park; Sean M Ward; Ju Hyeong Lyu; Young-Kug Choo
Journal:  Int J Mol Sci       Date:  2019-12-22       Impact factor: 5.923

Review 6.  Gangliosides as Signaling Regulators in Cancer.

Authors:  Norihiko Sasaki; Masashi Toyoda; Toshiyuki Ishiwata
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

7.  How Do Gangliosides Regulate RTKs Signaling?

Authors:  Sylvain Julien; Marie Bobowski; Agata Steenackers; Xuefen Le Bourhis; Philippe Delannoy
Journal:  Cells       Date:  2013-12-06       Impact factor: 6.600

8.  Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance.

Authors:  Leah K O'Shea; Samar Abdulkhalek; Stephanie Allison; Ronald J Neufeld; Myron R Szewczuk
Journal:  Onco Targets Ther       Date:  2014-01-16       Impact factor: 4.147

9.  Identification of ganglioside GM2 activator playing a role in cancer cell migration through proteomic analysis of breast cancer secretomes.

Authors:  Jihye Shin; Gamin Kim; Jong Won Lee; Ji Eun Lee; Yoo Seok Kim; Jong-Han Yu; Seung-Taek Lee; Sei Hyun Ahn; Hoguen Kim; Cheolju Lee
Journal:  Cancer Sci       Date:  2016-04-27       Impact factor: 6.716

10.  Metabolic flux-driven sialylation alters internalization, recycling, and drug sensitivity of the epidermal growth factor receptor (EGFR) in SW1990 pancreatic cancer cells.

Authors:  Mohit P Mathew; Elaine Tan; Christopher T Saeui; Patawut Bovonratwet; Samuel Sklar; Rahul Bhattacharya; Kevin J Yarema
Journal:  Oncotarget       Date:  2016-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.